IDiyas

For the Inventor, By the Inventor

Greenwood, IN, United States of America

David W Robertson

USPTO Granted Patents = 42

Average Co-Inventor Count = 1.8

ph-index = 11

Forward Citations = 524(Granted Patents)


Location History:

  • Indianapolis, IN (US) (1985 - 1990)
  • San Diego, CA (US) (1993)
  • Greenwood, IN (US) (1987 - 1996)
  • Poway, CA (US) (1995 - 1998)

Company Filing History:

goldMedal42 out of 4,442 
 
Eli Lilly and Company
 patents

Years Active: 1985-1998

Loading Chart...
42 patents (USPTO):Explore Patents
1. 5739146 - Substituted cyclo or bicycloalkylamides of (8.beta.)-6-(substituted) (1998-04-14),
2. 5563148 - Specific 5-HT3 antagonists (1996-10-08),
3. 5554640 - Use of propanolamine derivatives as selective 5-HT.sub.1 antagonists (1996-09-10),
4. 5442078 - Intermediates for specific 5-HT3 antagonists (1995-08-15),
5. 5441961 - Substituted cyclo or bicycloalkylamides of (8.beta.)-6-(substituted) (1995-08-15),
6. 5420294 - Cycloalkylaminoalkoxyindoles (1995-05-30),
7. 5364863 - Specific 5-HT.sub.3 antagonists (1994-11-15),
8. 5356934 - Selected serotonin subtype receptor agonist to treat sleep apnea (1994-10-18),
9. 5281624 - N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and (1994-01-25),
10. 5264445 - (-)-N'-cyano-N-3-pyridyl-N'-1,2,2-trimethylpropylguanidine (1993-11-23),
11. 5250572 - (R)-norfluoxetine in method for occupying serotonin IC receptors (1993-10-05),
12. 5250571 - (S)-norfluoxetine in method of inhibiting serotonin uptake (1993-10-05),
13. 5238959 - 3-phenyloxy-3-phenyl propanamines (1993-08-24),
14. 5141944 - N-(2-hydroxycyclopentyl)-1-isopropyl-6-methylergoline-8-carboxamides (1992-08-25),
15. 5135947 - 1-phenyl-3-naphthalenyloxypropanamines and their use as selective (1992-08-04),

Title: The Innovative Mind of David W Robertson: Pioneering Medicinal Treatments

Introduction: David W Robertson, a prolific inventor based in Greenwood, IN, has made significant contributions to the field of pharmaceuticals with an impressive portfolio of 42 patents. His groundbreaking work at Eli Lilly and Company has led to the development of novel compounds that target specific receptors in the human body, offering hope for a range of medical conditions.

Latest Patents:

- Robertson's recent patents include Substituted cyclo or bicycloalkylamides of (8.beta.)-6-(substituted): These compounds have shown promise in occupying 5HT.sub.2 or 5HT.sub.1.sbsb.c receptors, with potential applications in treating various disorders affecting these receptors.

- Another notable invention is his development of specific 5-HT3 antagonists, which have shown efficacy in treating conditions such as migraine, emesis, gastrointestinal disorders, schizophrenia, and anxiety in mammals.

Career Highlights:

- David W Robertson's career at Eli Lilly and Company has been marked by a relentless pursuit of innovation in drug discovery and development.

- His expertise in medicinal chemistry and pharmacology has paved the way for the creation of groundbreaking pharmaceutical formulations that have the potential to revolutionize patient care.

Collaborations:

- Robertson has collaborated closely with esteemed colleagues such as David T Wong and Marlene L Cohen, leveraging their collective expertise to advance the field of pharmacology.

- These collaborations have not only enhanced the quality of research at Eli Lilly and Company but have also fostered a culture of innovation and collaboration within the organization.

Conclusion: David W Robertson's remarkable achievements in the realm of pharmaceutical inventions stand as a testament to his unwavering commitment to advancing medical science. His inventive spirit and collaborative approach have laid the foundation for transformative treatments that have the potential to improve the lives of countless individuals.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…